NASDAQ:DHC · Diversified Healthcare Trust - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.54B | $1.50B | $1.41B | $1.28B | $1.38B | $1.63B |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $45.50M | $26.52M | $26.13M | $26.43M | $34.09M | $30.59M |
| Total Operating Expenses | $1.74B | $1.62B | $1.51B | $1.38B | $1.41B | $1.64B |
| D&A | $261.92M | $284.96M | $284.08M | $239.28M | $271.13M | $270.15M |
| Operating Income | ($320.90M) | ($371.38M) | ($272.67M) | $181.36M | ($133.06M) | ($133.06M) |
| Interest Expense | $204.50M | $235.24M | $191.78M | $209.38M | $255.76M | $201.48M |
| Income Tax | $1.74M | $467.0K | $445.0K | $710.0K | $1.43M | $1.25M |
| Net Income | ($285.89M) | ($370.25M) | ($293.57M) | ($15.77M) | $174.51M | ($139.45M) |
| EPS - Basic | ($1.19) | ($1.55) | ($1.23) | ($0.07) | ($0.59) | - |
| EPS - Diluted | ($1.19) | ($1.55) | ($1.23) | ($0.07) | ($0.59) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $105.41M | $144.58M | $245.94M | $658.07M | $634.85M | $74.42M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - |
| Current Assets | - | - | - | - | - | - |
| Total Assets | $4.36B | $5.14B | $5.45B | $6.00B | $6.62B | $6.48B |
| Current Liabilities | - | - | - | - | - | - |
| Long-term Debt | $2.44B | $3.05B | - | - | - | - |
| Total Liabilities | $2.70B | $3.18B | $3.11B | $3.36B | $3.96B | $3.86B |
| Stockholders' Equity | $1.67B | $1.96B | $2.64B | $2.64B | $2.66B | $2.50B |
| Retained Earnings | $1.12B | $1.41B | $1.78B | $2.07B | $2.09B | $1.91B |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($19.62M) | $112.22M | $10.48M | ($40.35M) | ($63.32M) | $158.54M |
| Investing Cash Flow | $483.57M | ($187.02M) | ($202.11M) | $387.71M | $242.70M | ($40.44M) |
| Financing Cash Flow | ($492.01M) | ($22.31M) | ($249.71M) | ($676.00M) | $746.72M | ($79.48M) |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -20.9% | -24.8% | -19.3% | 14.1% | -9.6% | -8.2% |
| EBITDA margin | -3.8% | -5.8% | 0.8% | 32.8% | 10.0% | 8.4% |
| Net margin | -18.6% | -24.8% | -20.8% | -1.2% | 12.6% | -8.5% |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 3.0% | 1.8% | 1.9% | 2.1% | 2.5% | 1.9% |
| Effective tax rate | - | - | - | - | 0.8% | - |
| Return on assets | -6.6% | -7.2% | -5.4% | -0.3% | 2.6% | -2.2% |
| Return on equity | -17.2% | -18.9% | -11.1% | -0.6% | 6.6% | -5.6% |
| Return on invested capital | -6.2% | -5.9% | - | - | - | - |
| Liquidity | ||||||
| Current ratio | - | - | - | - | - | - |
| Quick ratio | - | - | - | - | - | - |
| Cash ratio | - | - | - | - | - | - |
| Leverage | ||||||
| Debt / Equity | 1.47 | 1.56 | - | - | - | - |
| Debt / Assets | 0.56 | 0.59 | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -1.6x | -1.6x | -1.4x | 0.9x | -0.5x | -0.7x |
| Equity multiplier | 2.62 | 2.62 | 2.06 | 2.27 | 2.49 | 2.59 |
| Liabilities / Assets | 0.62 | 0.62 | 0.57 | 0.56 | 0.60 | 0.60 |
| Efficiency | ||||||
| Asset turnover | 0.35 | 0.29 | 0.26 | 0.21 | 0.21 | 0.25 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 2.8% | 6.0% | 9.9% | -7.2% | -15.2% | 56.9% |
| Revenue CAGR (3y) | 6.2% | 2.6% | -4.8% | 7.3% | 9.3% | 14.9% |
| Revenue CAGR (5y) | -1.2% | 7.5% | 5.9% | 3.6% | 5.5% | 10.3% |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 13.6% | -36.2% | - | - | 0.0% | -60.6% |
| Net income growth (YoY) | 22.8% | -26.1% | -1761.1% | - | - | -58.0% |
| EPS growth (YoY) | 23.2% | -26.0% | -1657.1% | 88.1% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -15.0% | -25.8% | 0.0% | -0.9% | 6.7% | -8.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$1.51B totalSenior Housing Operating Portfolio Segment$1.31B · 87.1%
Medical Office And Life Science Portfolio Segment$193.81M · 12.9%
Product / service
$1.54B totalResident Fees And Services$1.31B · 85.4%
Rental Income$225.20M · 14.6%
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- -Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Real Estate Investment Trusts
Comparing DIVERSIFIED HEALTHCARE TRUST against the 5 most active filers in the same SIC group.